Long-term safety and efficacy of high-dose atorvastatin treatment in patients with familial hypercholesterolemia.

Abstract

In the 2-year Atorvastatin versus Simvastatin on Atherosclerosis Progression extension study, patients with familial hypercholesterolemia who continued to take atorvastatin 80 mg for an additional 2 years had complete arrest of the progression of mean carotid intima-media thickness (0.89 mm at the start vs 0.90 mm at the end of the study, p = 0.58). In contrast, patients previously taking simvastatin 40 mg had significant regression of intima-media thickness (0.95 mm at the start vs 0.92 mm at the end of the study, p = 0.01). Therefore, both placebo- and statin-treated patients with familial hypercholesterolemia are best treated with high-dose atorvastatin, a therapeutic regimen that induces atherosclerosis regression and is safe and well tolerated over a 4-year period.

• Authors: Sanne van Wissen, Tineke J Smilde, Mieke D Trip, Anton F H Stalenhoef, John J P Kastelein
• Journal: The American journal of cardiology (Am J Cardiol) Vol. 95 Issue 2 Pg. 264-6 (Jan 15 2005) ISSN: 0002-9149 [Print] United States
• PMID: 15642565 (Publication Type: Evaluation Study, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Cholesterol, HDL
• Cholesterol, LDL
• Heptanoic Acids
• Hydroxymethylglutaryl-CoA Reductase Inhibitors
• Pyrroles
• Triglycerides
• Cholesterol
• Atorvastatin

Topics

• Adult
• Aged
• Atorvastatin
• Cholesterol (blood)
• Cholesterol, HDL (blood)
• Cholesterol, LDL (blood)
• Coronary Artery Disease (blood, drug therapy, pathology)
• Drug Administration Schedule
• Female
• Heptanoic Acids (administration & dosage)
• Humans
• Hydroxymethylglutaryl-CoA Reductase Inhibitors (administration & dosage)
• Hyperlipoproteinemia Type II (blood, drug therapy, pathology)
• Longitudinal Studies
• Male
• Middle Aged
• Pyrroles (administration & dosage)
• Randomized Controlled Trials as Topic
• Treatment Outcome
• Triglycerides (blood)